US SEC Filing Intelligence

VA Healthcare & Services Contracts — April 18, 2026

The VA Healthcare & Services Contracts stream reflects a single $928,900,085 obligation to TriWest Healthcare Alliance Corp from the Department of Veterans Affairs, with a 0/1 defense-related split indicating fully civilian exposure. This high-materiality firm fixed price delivery order for health and medical insurance carriers (NAICS 524114, PSC G007) under full and open competition carries a neutral highest-conviction signal (strength 5/10) due to its anomalous one-month performance period in March 2026 and no funds outlayed despite total obligation matching base + options. The dominant agency theme is Department of Veterans Affairs health insurance programs via delivery order, lacking multi-year visibility. Key risk is the award date (2026-04-16) post-dating performance end (2026-03-31), introducing execution uncertainty and high pricing risk.

New Federal Contractors — April 18, 2026

These 6 new federal contracts total $4,180,930,218 in obligations, entirely civilian with 0 defense-related awards, led by health and human services themes from HHS ($2.78B to MAXIMUS FEDERAL SERVICES, INC.) and VA ($928.9M to TRIWEST HEALTHCARE ALLIANCE CORP). Dominant agencies include HHS, VA, GSA, EPA, and NASA, signaling civilian health insurance and engineering services momentum. Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering delivery order (strength 8/10), supporting DTRA IMAX DA with low pricing risk. Key risk is data anomalies including $0 outlayed for TriWest VA contract, negative -$530K outlayed for CACI, and post-performance award dates, warranting funds progress monitoring.

Significant Contract Modifications ($10M+) — April 18, 2026

These six significant contract modifications totaling $4,180,930,218 in obligations are entirely civilian (0/6 defense-related), dominated by health and human services themes from HHS ($2.78B to MAXIMUS FEDERAL SERVICES, INC.) and VA ($928.9M to TRIWEST HEALTHCARE ALLIANCE CORP). Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering services delivery order (strength 8/10), supporting DTRA IMAX DA with low pricing risk under cost-plus-award-fee structure. Lockheed Martin secures two minor NASA space R&D contracts totaling $6M, but with low materiality. Key risk is data anomalies including zero outlays on TriWest's $928.9M VA award, negative outlays (-$530K) on CACI, and future-dated performance periods conflicting with April 2026 award dates.

Contract Deobligations Alert — April 18, 2026

$4,180,930,218 in contract deobligations across 6 civilian awards (0/6 defense-related) highlight volatility in HHS, VA, GSA, EPA, and NASA spending, with average signal strength of 4.7/10. Dominant agency theme is health services via HHS ($2.78B to MAXIMUS FEDERAL SERVICES, INC.) and VA ($928.9M to TRIWEST HEALTHCARE ALLIANCE CORP.), alongside GSA engineering ($399.6M to CACI NSS, LLC). Highest-conviction bullish signal is CACI NSS, LLC's $399.6M cost-plus-award-fee delivery order from GSA, signaling low pricing risk and potential extension to 2026. Balanced view shows neutral execution risks from zero or negative outlays in top awards. Key watch item: TriWest's $928.9M award dated post-performance period (2026-04-16 after March 2026 end), risking non-execution.

Contract Option Exercises — April 18, 2026

These six contract option exercises total $4,180,930,218 in obligations, with 0/6 defense-related and fully civilian agency focus across HHS, VA, GSA, EPA, and NASA. Dominant themes include health and medical insurance services (HHS MAXIMUS FEDERAL SERVICES, INC. at $2.78B and VA TRIWEST HEALTHCARE ALLIANCE CORP at $928.9M) and engineering/R&D support. Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering delivery order (strength 8/10), signaling durable cost-plus award fee revenue through potential 2026 extension. Key risk is data anomalies including TriWest's $0 outlayed with future performance dates (March 2026) and CACI's negative -$530K outlayed, warranting close funds progress monitoring.

Federal Professional Services Contracts — April 18, 2026

Across one federal professional services contract in the April 18, 2026 period, total obligations reached $399,565,757, with a 0/1 defense/civilian split entirely in the civilian sector via GSA Federal Acquisition Service's FEDSIM office. The dominant theme is engineering services (NAICS 541330) supporting DTRA IMAX DA, highlighted by CACI NSS, LLC's $399,565,757 delivery order awarded in 2021 under full and open competition. Highest-conviction signal is bullish for CACI INTERNATIONAL INC, signaling ~$80M annual revenue potential over a 5-year period if options extend to June 29, 2026. Key risk is execution uncertainty from negative total outlayed of -$530,151 and current end date of June 29, 2023, warranting watch on option exercises.

All HHS Contracts — April 18, 2026

HHS drove 100% of the $2,779,736,793 in total obligations during April 18-18, 2026, with a 0/1 defense-related split confirming purely civilian exposure. MAXIMUS FEDERAL SERVICES, INC. captured the entirety of this value via a single $2.78B award, marking the dominant agency and contractor theme in HHS services. The highest-conviction signal is bullish for MAXIMUS at 7/10 strength and 8/10 materiality, underscoring potential revenue tailwinds in government services. A key watch item is the unknown competition signal, which could expose the award to protests or re-competes given the contract's scale.

Mega Contracts Monitor ($100M+) — April 18, 2026

Three civilian mega contracts totaling $4,108,202,635 were awarded across HHS, VA, and GSA, with zero defense-related obligations, highlighting robust demand in health administration, insurance, and engineering services. Dominant themes center on VA and HHS health/insurance programs alongside GSA engineering support, led by MAXIMUS FEDERAL SERVICES, INC.'s $2.78B HHS award as the highest materiality bullish signal at 8/10. CACI NSS, LLC's $399.6M GSA delivery order adds a high-conviction bullish signal (8/10 strength) for engineering services with potential extension to 2026. TRIWEST HEALTHCARE ALLIANCE CORP's $928.9M VA order remains neutral due to data anomalies including zero funds outlayed and post-performance award date. Key watch item: monitor TriWest funds outlay progress and CACI option exercises beyond June 29, 2023 amid negative outlays.

3 total filings

High-Value Federal Grants ($5M+) — April 18, 2026

High-value federal grants totaling $4,174,924,202 were awarded across four civilian contracts from April 18, 2026, with zero defense-related activity, highlighting pure civilian agency exposure in health services, engineering, and environmental remediation. Dominant themes center on Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) health/insurance programs, comprising over 90% of value via MAXIMUS FEDERAL SERVICES, INC. ($2.78B) and TRIWEST HEALTHCARE ALLIANCE CORP. ($929M). Highest-conviction bullish signal is CACI NSS, LLC's $399.6M GSA engineering delivery order (strength 8/10), supporting potential revenue of $80M/year through 2026. Key risk is execution anomalies, including TRIWEST's $0 outlay and post-performance award date, plus CACI's negative -$530K outlayed.

General Federal Contracts — April 18, 2026

These four civilian contracts total $4,174,924,202 in obligations with 0/4 defense-related, highlighting HHS and VA dominance in health services alongside GSA engineering and EPA remediation. MAXIMUS FEDERAL SERVICES, INC. leads with a massive $2.78B HHS award, while CACI NSS, LLC secured a bullish $399.6M GSA engineering delivery order. Highest-conviction signal is CACI's Cost Plus Award Fee structure with low pricing risk and potential extension to 2026. Key risk is data anomalies including TriWest's $928.9M VA award with future performance dates (March 2026) post-award (April 2026) and $0 outlay, plus CACI's negative -$530K outlay.

All NASA Contracts — April 18, 2026

NASA awarded $6,006,015 in total obligations across two contracts to Lockheed Martin Corporation from NASA Glenn Research Center, representing a 100% civilian split with 0/2 defense-related awards. The dominant theme is basic space R&D services (PSC AR11, NAICS 541715) under cost-plus-fixed-fee structures, both non-competed with no set-asides. Highest-conviction signal is neutral (avg strength 2/10, materiality 1/10), reflecting minor revenue additions for Lockheed Martin amid ongoing NASA basic research funding. Both contracts show significant outlays ($3,210,919 and $2,264,952 respectively) with options unexercised, signaling low execution risk but limited upside. Key watch item: monitor option exercises to reach $3,871,841 and $2,671,620 ceilings by performance end date of 2026-06-30.

2 total filings

Biotech Small-Cap Approvals — April 17, 2026

The FDA recorded 4 'Other' (fallback) approvals from April 13-15, 2026, categorized as 0 NMEs, 0 biosimilars, 0 label expansions, all with neutral signals. These involve small-molecule generic-style entries by MSN (GLYCEROL PHENYLBUTYRATE), APOTEX (CANAGLIFLOZIN), MICRO LABS (HYDROCHLOROTHIAZIDE), and NOVITIUM PHARMA (PIMOZIDE), spanning disparate therapeutic areas with no dominant theme. Highest-conviction signal is NOVITIUM PHARMA's PIMOZIDE approval (neutral, 5/10 strength and materiality), implying routine market entry with commercial details NOT_DISCLOSED. Key risk/watch item: Potential revenue pressure on originators from these entrants, balanced by neutral entrant upside absent peak sales or exclusivity data.

Orphan Drug Approvals — April 17, 2026

This period featured 1 FDA orphan drug approval: 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other (fallback approval). No dominant therapeutic area theme emerged from the single approval. The highest-conviction bullish signal is Travere's Sparsentan (Filspari) label expansion, signaling portfolio strengthening in the orphan space with medium commercial materiality. Key risk/watch item is limited visibility into peak sales, exclusivity, pricing, and market position due to NOT_DISCLOSED data, warranting post-approval uptake monitoring.

New Drug Approvals (Original) — April 17, 2026

This period saw 4 Other approvals (0 NMEs, 0 biosimilars, 0 label expansions), all classified as fallback with neutral signals for generic/biosimilar entrants MSN (GLYCEROL PHENYLBUTYRATE), APOTEX (CANAGLIFLOZIN), MICRO LABS (HYDROCHLOROTHIAZIDE), and NOVITIUM PHARMA (PIMOZIDE). No dominant therapeutic area theme emerges, as approvals span urea cycle disorders, diabetes/CVD, hypertension, and psychiatric indications without clustering. Highest-conviction signal is the neutral approval for GLYCEROL PHENYLBUTYRATE to MSN, signaling modest market entry opportunity for the sponsor amid NOT_DISCLOSED commercial metrics. Key risk/watch item: potential revenue pressure on unspecified originators from these generic/biosimilar entries, balanced by limited materiality (5/10). Overall, routine generic pipeline activity with no high-impact biotech catalysts.

Federal Construction & Infrastructure Contracts — April 17, 2026

The single contract in this Federal Construction & Infrastructure stream totals $63,074,577 in obligations, entirely civilian with zero defense exposure, dominated by Department of Commerce/NIST building renovation work. Whiting-Turner Contracting Company secured this full and open competition firm fixed price award in 2020, providing multi-year revenue visibility through October 2025 but with only $3,162,695 outlayed to date amid $17,284,290 in subawards. The highest-conviction signal is neutral (5/10 strength), balancing revenue potential against execution risks. No dominant sector growth theme emerges from this isolated civilian maintenance project. Key risk is high firm fixed price execution exposure; watch outlay acceleration and option exercises toward the $78,053,862 ceiling.

VA Healthcare & Services Contracts — April 17, 2026

Optum Public Sector Solutions, Inc., a subsidiary of UnitedHealth Group Incorporated, secured three firm fixed price delivery orders totaling $2,779,468,829 from the Department of Veterans Affairs, representing a major civilian allocation to managed healthcare services (PSC Q201, NAICS 524114) with zero defense exposure. These awards, spanning $1.1B, $894.5M, and $782.1M obligations, signal strong bullish conviction for UnitedHealth Group's VA healthcare revenue stream via full and open competition wins. The dominant theme is VA's FY26 Q1 emphasis on short-duration (one-month) medical-managed healthcare contracts in Fredericksburg, VA. Highest-conviction bullish signal stems from the two highest-materiality awards ($1.1B and $894.5M at 8/10 materiality). A key risk is execution uncertainty, as all contracts show $0 outlayed to date, performance periods in Nov-Dec 2025 precede the 2026-04-15 award date, and high pricing risk prevails.

3 total filings